Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 4 Smoldering Multiple Myeloma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Promyelocytic, Acute 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Gemcitabine 74 Capecitabine 60 Paclitaxel 59 Fluorouracil 58 Oxaliplatin 57 Bevacizumab 51 Docetaxel 50 Leucovorin 48 Nivolumab 40 Cisplatin 40 Irinotecan 39 Carboplatin 37 Cetuximab 34 pembrolizumab 32 Radiosurgery 32 Trastuzumab 30 Radiotherapy 27 Everolimus 24 Sorafenib 23 Pemetrexed 20 Doxorubicin 20 Albumin-Bound Paclitaxel 20 Ipilimumab 19 Cyclophosphamide 19 Panitumumab 18 Zoledronic Acid 17 Lapatinib 17 Erlotinib Hydrochloride 17 Prednisone 16 pazopanib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasm Metastasis × Maintenance × Clear all

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡